Autologous Cell Therapy: Your Own Cells as Medicine

Introduction: What Makes Autologous Different

Imagine if the most powerful medicine for your condition wasn't found in a pharmacy, but inside your own body. That's the revolutionary premise behind autologous cell therapy—using your own cells as medicine.

The word "autologous" simply means "from the same individual." Unlike traditional cell therapies that use donor cells from other people (called "allogeneic"), autologous treatments harvest, process, and return your own cells to heal your body. It's personalized medicine at its most literal level.

But here's where it gets interesting: for decades, autologous therapy faced a fundamental problem. If you're sick or elderly, your cells are often sick or aged too. Why would putting compromised cells back into your body help? Traditional thinking suggested it wouldn't—which is why many researchers turned to using healthy young donor cells instead.

The Rejection Problem

Donor cell therapies, while promising in concept, face a massive hurdle: your immune system. Your body has spent a lifetime learning to recognize and attack anything foreign. When you introduce cells from another person, even if they're healthy and young, your immune system often treats them as invaders. This can lead to rejection, inflammation, or the need for lifelong immunosuppressive drugs.

Think of it like an organ transplant—even when successful, patients typically require anti-rejection medications for life. With cellular therapies, this immune response can actually counteract the healing benefits you're seeking.

Why Autologous is the Gold Standard

Autologous therapy eliminates the rejection problem entirely. Your immune system recognizes these cells as "self" because they literally are. There's no foreign DNA, no incompatible proteins, no risk of graft-versus-host disease. Your body welcomes these cells home.

But the safety advantages go deeper than just immune compatibility. Autologous therapy also eliminates concerns about:

• Disease transmission from donors
• Ethical issues around embryonic or fetal tissue
• Supply chain dependencies on donor availability
• The need for tissue matching and compatibility testing

The Science Behind Using Your Own Cells

To understand why Celljevity's approach represents such a breakthrough, we need to understand how aging affects our cells at the molecular level.

How Cells Age and Lose Function

Every cell in your body contains the same DNA you were born with. But over time, the expression of that DNA changes—a process called epigenetic aging. Think of DNA as a vast library of instructions, and epigenetic factors as the librarians who decide which books get read and which stay on the shelf.

As we age, these cellular "librarians" start making different choices. Genes that promote healing and regeneration get silenced, while inflammatory pathways become overactive. Telomeres—the protective caps on chromosomes—shorten with each cell division. Mitochondria, the cellular powerhouses, become less efficient.

The result? Cells that remember how to be young but have forgotten how to access those instructions.

Traditional Limitations: The Catch-22

This created what seemed like an impossible situation for autologous therapy. Patients with age-related diseases like Alzheimer's, arthritis, or autoimmune conditions have cells that are either:

• Too old to be therapeutically effective
• Too few in number due to disease-related damage
• Too compromised by the same processes causing their illness

It was like trying to fix a broken car with parts from the same broken car.

Celljevity's Breakthrough: Cellular Time Travel

Here's where Celljevity changed everything. Instead of accepting that old cells can't be therapeutic, our scientists asked a different question: What if we could teach old cells to be young again?

Dr. Yi Eve Sun and her team at UCLA discovered that through precise treatment with specific small molecule compounds, they could essentially reprogram aged skin cells back to a youthful state. Not by changing their DNA, but by resetting their epigenetic programming—like teaching those cellular librarians to read from the right books again.

The 6mm x 6mm Solution

The process starts remarkably simply. During a brief outpatient procedure, a doctor takes a tiny sample of skin from behind your ear—just 6mm x 6mm, about the size of a pencil eraser. This location is chosen because it's hidden, heals quickly, and contains robust fibroblast cells.

Those skin cells, called fibroblasts, might seem unremarkable. But they're actually cellular Swiss Army knives—versatile cells capable of secreting growth factors, modulating immune responses, and supporting tissue repair throughout the body.

Clinical Evidence: Real Patients, Real Results

The true test of any medical breakthrough isn't in the laboratory—it's in real patients facing real challenges. Celljevity's autologous cell therapy has undergone rigorous clinical testing across multiple conditions, with results that speak for themselves.

Alzheimer's Disease: Preserving Precious Memories

In our Alzheimer's clinical trial, 37 patients received Prometheus cell therapy over six months. These weren't early-stage patients—they had MMSE scores between 3 and 20, indicating moderate to severe cognitive impairment.

The primary measurement was the ADAS-Cog scale, the gold standard for assessing cognitive function in Alzheimer's patients. In untreated patients, this score typically worsens by about 9 points per year, reflecting the relentless progression of the disease.

The results were striking. After six months of treatment, patients showed an average change of just 0.1 ± 5.2 points—essentially stabilizing their cognitive function. Even more encouraging, we saw significant improvements in specific domains:

• Memory function (p=0.031)
• Processing speed (p=0.010)
• Language abilities (p=0.004)
• Global cognition (p=0.002)

Translation: Instead of losing ground to Alzheimer's, patients maintained their cognitive abilities and even showed improvement in key areas.

Autoimmune Conditions: Resetting the Immune System

Our autoimmune study included 56 patients with various conditions: rheumatoid arthritis (26 patients), primary Sjögren's syndrome (18 patients), mixed connective tissue disease (5 patients), and systemic lupus erythematosus (7 patients).

The results were remarkable:

• Over 90% of patients reported meaningful symptom relief
• Blood markers of inflammation (STAT1 and IRF7) normalized
• C-reactive protein levels decreased significantly
• Patients reported improved quality of life across multiple measures

What made this particularly significant was that we were treating the underlying immune dysfunction, not just managing symptoms. Single-cell RNA sequencing showed actual changes in immune cell populations, suggesting a fundamental reset of the immune system.

Osteoarthritis: Getting People Moving Again

Perhaps our most rigorous study involved 80 patients with knee osteoarthritis. This was a controlled trial where each patient served as their own control—one knee received Prometheus cells, the other received saline placebo.

Using the WOMAC scale (the standard measure for arthritis pain and function), we tracked patients for six months:

• Treatment group: 7.72 ± 9.66 points
• Control group: 21.70 ± 14.71 points
• Statistical significance: p=0.02

But the numbers only tell part of the story. In practical terms:

• 67% of patients achieved clinically meaningful improvement (more than 12% on WOMAC scale)
• 90% of patients reported better recovery with their treated knee
• MRI imaging showed actual cartilage regeneration

Safety: The Foundation of Trust

Across all studies, encompassing over 170 patients and thousands of individual treatments, we've recorded zero serious adverse events related to Prometheus cell therapy. No infections, no tumors, no immune reactions—just the intended therapeutic effects.

This safety profile isn't accidental. It reflects the fundamental advantage of autologous therapy: we're working with your body, not against it.

How It Works: The 15-Day Transformation

The journey from skin sample to therapeutic cells is a carefully orchestrated process that combines cutting-edge science with pharmaceutical-grade quality control.

Small Molecule Induction: Teaching Old Cells New Tricks

Once your skin cells arrive at our GMP-certified laboratory, they begin a remarkable 15-day transformation. The cells are treated with our proprietary combination of small molecule compounds—carefully selected chemicals that can cross cell membranes and influence gene expression.

These aren't random chemicals but precisely chosen molecular signals that activate dormant pathways associated with cellular youth. Think of them as molecular "wake-up calls" that remind cells how to behave like their younger selves.

90% Success Rate: Consistency You Can Count On

The induction process works with remarkable reliability. Over 90% of patient samples successfully transform into rejuvenated cells—what we call auto-rFib (autologous rejuvenated fibroblasts) or Prometheus cells.

This high success rate is crucial for therapeutic applications. It means nearly every patient who begins the process will have viable cells for treatment, eliminating the uncertainty that plagues many experimental therapies.

20 Billion Therapeutic Cells: Massive Scale from Tiny Sample

From that pencil-eraser-sized skin sample, we generate approximately 20 billion therapeutic cells. To put this in perspective, that's enough cells to provide multiple treatments, with each treatment containing tens of millions of highly active, rejuvenated cells.

These cells aren't just numerous—they're functionally young. Laboratory analysis shows telomere lengths comparable to cells from children, proliferation rates that rival embryonic cells, and secretion profiles rich in growth factors and healing signals.

Quality Control: Single-Cell Precision

Before any cells leave the laboratory, they undergo the most advanced quality control testing available: single-cell RNA sequencing. This "molecular microscope" analyzes gene expression in individual cells, confirming:

• Cellular identity and purity
• Youthful gene expression patterns
• Absence of malignant transformation
• Batch-to-batch consistency

This level of quality control goes far beyond traditional cell therapies, providing molecular-level proof that the rejuvenation process worked as intended.

Advantages Over Other Therapies

Autologous cell therapy offers compelling advantages over both conventional treatments and other regenerative approaches.

No Immune Rejection Risk

Unlike donor cell therapies, there's zero risk of immune rejection. Your cells remain genetically identical to you throughout the process. The rejuvenation occurs at the epigenetic level—changing how genes are expressed, not the genes themselves.

No Ethical Concerns

Autologous therapy sidesteps entirely the ethical debates surrounding embryonic stem cells or fetal tissue. These are your own adult cells, ethically obtained with your full consent.

Personalized to Your Genetic Makeup

Every person's cells are unique, carrying their individual genetic signature and adapted to their specific physiology. Autologous therapy preserves this personalization while adding the therapeutic benefits of cellular rejuvenation.

Long-Lasting Effects Through System Reset

Rather than providing temporary symptomatic relief, Prometheus cells work by resetting fundamental biological processes. They modulate immune function, enhance cellular repair mechanisms, and promote regeneration at the tissue level. The effects can persist long after the cells themselves have integrated into your system.

No Need for Lifelong Medications

Unlike organ transplants that require permanent immunosuppression, or chronic conditions that demand daily medications, autologous cell therapy works with your body's natural healing systems. Many patients experience sustained benefits without ongoing pharmaceutical intervention.

What Conditions Can Be Treated

Celljevity's platform technology addresses the underlying cellular dysfunction common to many age-related and degenerative conditions.

Neurodegenerative Diseases

Our clinical results in Alzheimer's disease demonstrate the potential for treating neurodegenerative conditions. The intranasal delivery route allows cells to reach the brain directly, bypassing the blood-brain barrier. Current research extends to:

• Parkinson's disease
• Amyotrophic lateral sclerosis (ALS)
• Multiple sclerosis
• Stroke recovery
• Traumatic brain injury

Autoimmune Disorders

The immune system reset achieved through Prometheus cell therapy has shown remarkable results across multiple autoimmune conditions:

• Rheumatoid arthritis
• Systemic lupus erythematosus
• Sjögren's syndrome
• Mixed connective tissue disease
• Multiple sclerosis
• Type 1 diabetes (research stage)

Musculoskeletal Conditions

Beyond our proven osteoarthritis results, the technology shows promise for various joint and bone conditions:

• Osteoporosis
• Muscle atrophy
• Cartilage defects
• Tendon and ligament injuries
• Spinal disc degeneration

Metabolic Dysfunction

Early research suggests benefits for metabolic conditions where cellular aging plays a role:

• Type 2 diabetes
• Metabolic syndrome
• Organ-specific aging
• Wound healing disorders

The Patient Journey

Understanding what to expect can help you make informed decisions about whether autologous cell therapy is right for you.

Initial Consultation and Screening

Your journey begins with a comprehensive evaluation by our medical team. This includes:

• Review of your medical history and current condition
• Physical examination and baseline assessments
• Laboratory tests to establish current health status
• Discussion of treatment goals and expectations
• Evaluation of inclusion and exclusion criteria

Not every patient is a candidate for every type of treatment. Our team works carefully to match the therapy to your specific condition and health status.

Skin Biopsy Procedure

The biopsy is a simple outpatient procedure typically taking less than 30 minutes:

• Local anesthesia is applied to the area behind your ear
• A small circular sample (6mm x 6mm) is removed using a standard dermatological punch biopsy tool
• The area is closed with a few small stitches
• You can return to normal activities immediately
• The sample is immediately transported to our laboratory under strict temperature and timing controls

Cell Preparation Timeline

Once your sample reaches our GMP facility, the transformation process begins:

• Days 1-3: Cell isolation and initial culture
• Days 4-18: Small molecule induction and reprogramming
• Days 19-21: Expansion and quality control testing
• Days 22-24: Final preparation and release testing
• Day 25: Cells are ready for therapeutic use

Throughout this process, you'll receive regular updates on progress, and any concerns are addressed immediately.

Treatment Administration

Prometheus cell therapy uses a dual delivery approach designed to maximize therapeutic benefit:

Intravenous Infusion: 100ml containing 40-50 million cells administered over 1-2 hours in a comfortable clinical setting. This systemic delivery targets circulating immune cells and supports whole-body regeneration.

Intranasal Administration: 0.1ml per nostril containing 3 million cells. This route provides direct access to the central nervous system via olfactory pathways, particularly important for neurological conditions.

The treatment is typically administered once weekly for multiple cycles, depending on your specific condition and response.

Follow-up and Monitoring

Your care doesn't end with treatment. Comprehensive follow-up includes:

• Regular clinical assessments using validated measurement scales
• Laboratory monitoring of biomarkers and immune function
• Single-cell RNA sequencing to track therapeutic response
• Imaging studies when appropriate
• Quality of life assessments
• Long-term safety monitoring

Looking Forward

Autologous cell therapy represents just the beginning of a new era in regenerative medicine.

Regulatory Pathway and Approvals

We're actively working with regulatory authorities to bring this therapy to more patients:

• WHO International Clinical Trials Registry Platform registration ensures transparency
• GCP-compliant trials provide the safety and efficacy data needed for approvals
• Orphan drug designation strategies for rare diseases like ALS may accelerate patient access
• International regulatory harmonization efforts are underway

Expanding to More Conditions

Our research pipeline continues to grow:

• Spinal cord injury: Promising preclinical results in non-human primate models
• Cardiovascular disease: Research into cardiac regeneration applications
• Organ aging: Studies on liver, kidney, and other organ-specific applications
• Combination therapies: Integrating cell therapy with other regenerative approaches

Making Therapy Accessible Globally

Accessibility is a core value. We're developing:

• Regional treatment centers to reduce travel burden
• Partnerships with leading medical institutions worldwide
• Manufacturing capacity to meet growing demand
• Cost-reduction strategies as the technology scales

Your Cells, Your Future

Autologous cell therapy isn't just another treatment option—it's a fundamental shift in how we think about medicine. Instead of fighting against aging and disease with foreign interventions, we're empowering your own biology to remember its capacity for healing and regeneration.

The clinical evidence speaks clearly: your own cells, when given the right signals and environment, can become powerful agents of healing. From preserving cognitive function in Alzheimer's to resetting immune dysfunction in autoimmune diseases, from regenerating cartilage in arthritic joints to the promise of repairing spinal cord injuries—the applications seem limited only by our imagination and continued research.

But perhaps most importantly, autologous cell therapy offers something many patients have lost: hope backed by science. Not false promises or wishful thinking, but peer-reviewed clinical results showing real people getting their lives back.

Your journey toward cellular rejuvenation could begin with a simple conversation. Our patient support team is here to answer questions, explain the process, and help you determine if you're a candidate for this revolutionary therapy.

Because when your own cells become medicine, healing isn't just possible—it's personal.

---

Ready to explore if autologous cell therapy is right for you? Contact our patient support team to learn more about our current clinical programs and treatment options.

[Contact Us] [Clinical Trial Information] [Schedule Consultation]

This information is for educational purposes only and does not constitute medical advice. Autologous cell therapy is currently in clinical development. Please consult with qualified healthcare providers about your specific medical needs.